Preclinical Evidence of Nanomedicine Formulation to Target <i>Mycobacterium tuberculosis</i> at Its Bone Marrow Niche.

导出 LinkOut

翻译打印收藏纠错

作者： Jaishree,Garhyan ^[1] ; Surender,Mohan ^[1] ; Vinoth,Rajendran ^[2] ; Rakesh,Bhatnagar ^[3]

作者单位： Laboratory of Molecular Biology and Genetic Engineering, School of Biotechnology, Jawaharlal Nehru University, New Delhi 110067, India. ^[1] Department of Biochemistry, University of Delhi South Campus, Benito Juarez Road, New Delhi 110021, India. ^[2] Department of Microbiology, School of Life Sciences, Pondicherry University, Puducherry 605014, India. ^[3] Banaras Hindu University, Varanasi, Uttar Pradesh 221005, India. ^[4]

关键词 BM-MSCs Mtb bone-homing latent tuberculosis liposomes relapse stem cell niche

DOI 10.3390/pathogens9050372

PMID 32414000

发布时间 2020-09-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Pathogens (Basel, Switzerland)

2020年9卷5期

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Preclinical Evidence of Nanomedicine Formulation to Target <i>Mycobacterium tuberculosis</i> at Its Bone Marrow Niche.

Pathogens (Basel, Switzerland)

相似文献

Pathogens (Basel, Switzerland)

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Preclinical Evidence of Nanomedicine Formulation to Target <i>Mycobacterium tuberculosis</i> at Its Bone Marrow Niche.

Pathogens (Basel, Switzerland)

相似文献

Pathogens (Basel, Switzerland)

相关期刊

检索历史清除